FLOW’s kidney and cardiovascular outcome
The primary kidney composite includes death from cardiovascular causes. The organ named in a trial only begins to describe its outcome.
The people enrolled
FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Semaglutide reduced major kidney-disease events versus placebo, with a hazard ratio of 0.76 and a 95% confidence interval of 0.66-0.88. The report describes a 24% lower risk for its primary composite.
The seriousness of FLOW’s clinical question commands my respect. Chronic kidney disease gives the outcome a clinical setting, and type 2 diabetes further specifies the group. The result has much more substance with both diagnoses present than it would have as a claim about supporting kidneys.
The cardiovascular component inside a kidney outcome absorbs me. The page division into heart and kidney is convenient, but the trial’s primary measure crosses it. Wellness sounds broad to my ear; this overlap gives that breadth a specific clinical subject.
FLOW’s composite outcome
The primary kidney composite in FLOW included kidney failure, at least a 50% decline in eGFR, or death from kidney or cardiovascular causes. eGFR is an estimate of kidney filtration. The cardiovascular part of this outcome is easy to overlook when the trial is introduced simply as a kidney study.
That collection of events is the subject of the 24% lower-risk result. It would take more information to assign the same reduction to any single component. The combined outcome acknowledges several serious possibilities for this group and demands care about which result is being described.
My preferred next question concerns the particular circumstances in which these participants benefited, and the treatment burdens that accompanied benefit. I would need more than a broad organ-health claim to answer it. The heart page offers a related warning about summarising an organ result too neatly: cardiovascular findings and diabetic eye complications can coexist in a trial.